Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New wire device aims to unclog leg arteries without surgery

NCT ID NCT05869435

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new tool called the FastWire System in 8 people with severely blocked leg arteries. The goal was to see if the device could safely cross the blockage and allow doctors to place other treatments to restore blood flow. The study focused on safety and whether the device worked as intended during the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

8 people

The number who actually took part.

Started

Dec 2022

Finished

Jan 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient, or the patient's legal guardian has signed and dated an Informed Consent Form. 2. Aged between 18 years and 85 years (inclusive). 3. Severe claudication assessed as Rutherford category 3 or CLTI assessed as Rutherford category 4 or 5 LEAD. 4. Angiographic confirmation of a de novo, CTO, infrainguinal ligament including above the knee, below the knee, or below the ankle vessels. Exclusion Criteria: 1. Life expectancy of less than 12 months. 2. Females who are pregnant or lactating (urine test for women of childbearing age). 3. Myocardial infarction or stroke in two months prior to the index procedure. 4. Known, unstable coronary artery disease or other, uncontrolled comorbidity. 5. Any known haemorrhagic or coagulation deficiency. 6. Evidence of active infection, including but not limited to the target limb. 7. Current use of cocaine or other substance of abuse. 8. Patients who have received any thrombolytic therapy in the last two weeks. 9. History of severe allergy or contraindication, to contrast medium or other medications used during or after endovascular therapy. 10. Subject participating in another study involving an investigational drug or device 11. Patient has surgery or vascular intervention planned within 30 days of the index procedure. 12. Patient has had a previous peripheral bypass that includes the target vessel. 13. Patient has had a previous intervention in the target CTO (angioplasty, stenting) including at time of index procedure. 14. Patient tests positive for coronavirus disease (COVID-2019), as per site standard practice. 15. Estimated Glomerular Filtration Rate (eGFR) of less than 30 ml/min. 16. Platelet count \< 50,000.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic total occlusion of arteries of the extremities are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • INDEN

    Santo Domingo, Dominican Republic